Gefitinib enhances arsenic trioxide (AS2 O3 )-induced differentiation of acute promyelocytic leukemia cell line

Abstract Gefitinib (Iressa, ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits growth, invasion and colony formation of various cancer cells. However, little is known about the effect of combination of gefitinib and arsenic trioxide (ATO) on differentiation of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia research 2010-11, Vol.34 (11), p.1501-1505
Hauptverfasser:	Noh, Eui-Kyu, Kim, Hawk, Park, Min Jae, Baek, Jin Ho, Park, Jae-Hoo, Cha, Seung Joo, Won, Jong-Ho, Min, Young Joo
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute promyelocytic leukemia Antineoplastic Combined Chemotherapy Protocols Arsenic trioxide 1 Arsenicals - pharmacology Arsenicals - therapeutic use Cell Differentiation - drug effects Cell Line, Tumor Differentiation Drug Synergism Extracellular Signal-Regulated MAP Kinases - metabolism Gefitinib Hematology, Oncology and Palliative Medicine Humans Leukemia, Promyelocytic, Acute - drug therapy Leukemia, Promyelocytic, Acute - pathology Oxides - pharmacology Oxides - therapeutic use Quinazolines - pharmacology Quinazolines - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!